Current management of castrate-resistant prostate cancer.
Current management of castrate-resistant prostate cancer.
复制标题
DOI：
10.3747/co.v17i0.718
复制
发表时间：
2010-09
期刊：
影响因子：
2.6
通讯作者：
S. Hotte;F. Saad
中科院分区：
文献类型：
--
作者：
S. Hotte;F. Saad
前列腺癌（PCa）是北美最常见的癌症。去势抵抗性前列腺癌呈现一系列疾病，从在没有转移或症状的情况下PSA水平升高，尽管进行了雄激素剥夺治疗，到转移和癌症症状的显著衰弱。去势抵抗性前列腺癌通常在雄激素剥夺治疗后出现新症状、PSA升高或骨扫描或计算机断层扫描显示新的疾病证据的患者中被怀疑。治疗机构和全身或局部治疗的选择取决于许多因素。本综述讨论了去势抵抗性前列腺癌患者目前可用的各种治疗方法，从二级激素操作到多西他赛后全身治疗的选择。
Prostate cancer (PCa) is the most frequently diagnosed cancer in North America. Castrate-resistant PCa presents a spectrum of disease ranging from rising PSA levels in the absence of metastases or symptoms and despite androgen-deprivation therapy, to metastases and significant debilitation from cancer symptoms. Castrate-resistant PCa is usually suspected in patients with new symptoms on androgen deprivation therapy, with a rising PSA, or with new evidence of disease on bone scans or computed tomography scans. Institution of treatment and the choice of systemic or local therapy depend on a number of factors. This review discusses the various currently available treatments for patients with castrate-resistant PCa, from secondary hormonal manipulations to options for post-docetaxel systemic therapy.